Open Access
Volume 9, Number 3, September 2019
Article Number 16
Number of page(s) 6
Published online 27 August 2019
  1. Hermansen M-LF, Hummelshø L, Lundsgaard D, Hornum L, Keller P. Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosuspatients. Lupus. 2012; 21: 1098–104. [CrossRef] [PubMed] [Google Scholar]
  2. Kim H, Jeon J, Jeong-Moon Y. Beta2-Microglobulin Can Be a Disease Activity Marker in Systemic Lupus Erythematosus. AJMS. 2010; 339(4): 337–40. [CrossRef] [Google Scholar]
  3. Kyttaris VC, Krishnan S, Tsokos GC. Systems biology in systemic lupus erythematosus: integrating genes, biology and immune function. Autoimmunity. 2006; 39: 705–9. [CrossRef] [PubMed] [Google Scholar]
  4. Badr Abeer M, El-Melligy Dalal Mohamed, Mostafa Heba, El Deeb Somaya. 1 Evaluation of Beta2-Microglobulin as a Possible Biomarker for Assessment of Disease Activity in Systemic Lupus Erythematosus and Chronic Kidney Disease. World J Med Sci. 2005; 12(1): 26–35. [Google Scholar]
  5. Kanne JP, Yandow DR, Haemel AK, Meyer CA. Beyond Skin deep: thoracic manifestations of systemic disorders affecting the skin. Radiographics. 2011; 31: 1651–68. [CrossRef] [PubMed] [Google Scholar]
  6. Midgly A. Systemic Lupus Erythematosus (SLE). Category: Immune Dysfunction. British Society for Immunology. Bitsized Immunology. 2018. [Google Scholar]
  7. Hochberg MC, Boyd RE, Ahearn JM, Arnett FC, Bias WB, Provost TT, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore). 1985; 64(5): 285–95. [CrossRef] [PubMed] [Google Scholar]
  8. Davies K, Bukhari M, Ottewell L. Acroosteolysis in a patient with systemic lupus erythematosus/mixed connective tissue disease. Rheumatology (Oxford). 2018; 12: 1–8. [Google Scholar]
  9. Mira-Avendano IC, Abril A. Pulmonary manifestations of Sjögren syndrome, systemic lupus erythematosus, and mixed connective tissue disease. Rheum Dis Clin North Am. 2015; 41(2): 263–77. [CrossRef] [PubMed] [Google Scholar]
  10. Williams JN, Chang SC, Sinnette C, Malspeis S, Parks CG, Karlson EW, et al. Pesticide exposure and risk of systemic lupus erythematosus in an urban population of predominantly African-American women. Lupus. 2018; 27(13): 2129–34. [CrossRef] [PubMed] [Google Scholar]
  11. Ho Ch. Lupus Erythematosus, Drug-Induced. StatPearls Internet. Treasure Island (FL): StatPearls. 2018; 1–8. [Google Scholar]
  12. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009; 301(1): 99–105. [CrossRef] [PubMed] [Google Scholar]
  13. Chlebus E, Wolska H, Blaszczyk M, Jablonska S. Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications. J Am Acad Dermatol. 1998; 38(3): 405–12. [CrossRef] [PubMed] [Google Scholar]
  14. Tony E, Mohammed H, Fathi N, Tonys Abeer A, Afifi Ola, Abdou Madleen Adel A, Gamal Rania M. Serum and Urinary Biomarkers, Endothelin-1, Beta-2 Microglobulin, Cystatin C, Galectin-3 and Alpha-1-acid Glycoprotein; Can they Surrogate Clinical and Histological Staging in Lupus Nephritis Patients?. J Arthritis. 2016; 5: 6–9. [Google Scholar]
  15. Choi J. The Pathogenesis of Systemic Lupus Erythematosus – An Update. Curr Opin Immunol. 2012; 24(6): 651–7. [CrossRef] [PubMed] [Google Scholar]
  16. Delgado-Vega. Recent findings on genetics of systemic autoimmune diseases. Curr Opin Immunol. 2010; 22: 698–705. [CrossRef] [PubMed] [Google Scholar]
  17. Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010; 6: 683–92. [CrossRef] [PubMed] [Google Scholar]
  18. Taylor KE, Chung SA, Graham RR, Ortmann WA, Lee AT, Langefeld CD, et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 2011; 7: e1001311. [CrossRef] [PubMed] [Google Scholar]
  19. Skare T. Systemic lupus erythematosus activity and beta two microglobulin levels. Sao Paulo Med J. 2014; 132(4): 239–42. [CrossRef] [PubMed] [Google Scholar]
  20. Gladman DD, Ibenz D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol. 2002; 29: 288–91. [PubMed] [Google Scholar]
  21. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment lupus flares measured by the BILAG index. Rheumatology. 2003; 42: 1372–9. [CrossRef] [PubMed] [Google Scholar]
  22. Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Semin Immunopathol. 2005; 27: 276–85. [Google Scholar]
  23. Żychowska I, Suszek D, Dryglewska M, Majdan M. β2-micro- globulin as a marker of systemic lupus erythematosus activity. Adv Clin Exp Med. 2018; 27(3): 379–82. [CrossRef] [PubMed] [Google Scholar]
  24. Wibell LB. Studies on beta2-microglobulin in patients and normal subjects. Acta Clin Belg. 1976; 31: 14–26. [Google Scholar]
  25. Choe Y. Urine β2-microglobulin is associated with clinical disease activity and renal involvement in female patients with systemic lupus erythematosus. SAGE J. 2014; 8: 1–10. [Google Scholar]
  26. Teichmann LL, Ols ML, Kashgarian M, Reizis B, Kaplan DH, Shlomchik MJ. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity. 2010; 33: 967–78. [CrossRef] [PubMed] [Google Scholar]
  27. Bronson PG, Chaivorapol C, Ortmann W, Behrens TW, Graham RR. The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol. 2012; 1–9. [Google Scholar]
  28. Craft JE. Dissecting the immune cell mayhem that drives lupus pathogenesis. Sci Transl Med. 2011; 3: 73–9. [Google Scholar]
  29. Evrin PE, Strom T. Beta 2-microglobulin and its binding activity in serum from patients with SLE. Ann Rheum Dis. 1984; 43: 267–74. [CrossRef] [PubMed] [Google Scholar]
  30. Latt D, Weiss JB, Jayson MI. Beta 2-microglobulin levels in serum and urine of rheumatoid arthritis patients on gold therapy. Ann Rheum Dis. 1981; 40: 157–60. [CrossRef] [PubMed] [Google Scholar]
  31. Strom T, Evrin PE, Karlsson A. Serum beta-2-microglobulin in Sjogren’s syndrome. Scand J Rheumatol. 1978; 7: 97–100. [CrossRef] [PubMed] [Google Scholar]
  32. Yeung CK, Wong KL, Wong WS, Chan KH. beta 2-Microglobulin and systemic lupus erythematosus. J Rheumatol. 1986; 13(6): 1053–8. [PubMed] [Google Scholar]
  33. Żychowska Iwona. β2-microglobulin as a marker of systemic lupus erythematosus activity. Advances in Clinical and Experimental Medicine. Adv Clin Exp Med. 2018; 27(3): 379–82. [CrossRef] [PubMed] [Google Scholar]
  34. Hermansen ML, Hummelshøj L, Lundsgaard D, Hornum L, Keller P, Fleckner J, et al. Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients. Lupus. 2012; 21(10): 1098–104. [CrossRef] [PubMed] [Google Scholar]
  35. Font J. Serum beta 2-microglobulin as a marker of activity in systemic lupus erythematosus. Scand J Rheumatol. 1986; 15(2): 201–5. [CrossRef] [PubMed] [Google Scholar]
  36. Maury CP, Helve T, Sjoblom C. Serum beta 2-microglobulin, sialic acid, and C-reactive protein in systemic lupus erythematosus. Rheumatol Int. 1982; 2: 145–9. [CrossRef] [PubMed] [Google Scholar]
  37. Curry R, Thoen J, Shelborne C, Gaudernack G, Messner R. Antibodies to and elevations of beta 2 microglobulin in the serum of ankylosing spondylitis patients. Arthritis Rheum. 1982; 25: 375–80. [CrossRef] [PubMed] [Google Scholar]
  38. Karlsson FA, Wibell L, Evrin PE. Beta 2-microglobulin in clinical medicine. Scand J Clin Lab Invest Suppl. 1980; 154: 27–37. [PubMed] [Google Scholar]
  39. Wakabayashi K, Inokuma S, Matsubara E, Onishi K, Asashima H, Nakachi S, et al. Serum β2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adultonset Still’s disease. Clin Rheumatol. 2013; 32: 999–1005. [Google Scholar]
  40. Rezaeiyazddi Z. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus? SAGE Journal. 2011; 3: 1–5. [Google Scholar]
  41. Enocsson H, Sjöwall C, Kastbom A, Skogh T, Eloranta ML, Rönnblom L, et al. Association of serum C-reactive protein levels with lupus disease activity in the absence of measurable interferon-a and a C-reactive protein gene variant. Arthritis Rheumatol. 2014; 66(6): 1568–73. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.